Isolation of modified ubiquitin as a neutrophil chemotaxis inhibitor from uremic patients

Journal of the American Society of Nephrology

Volumn 9, Issue 3, 1998, Pages 451-456

  Cohen, Gerald ^a,b   Rudnicki, Michael ^a   Hörl, Walter H ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

UBIQUITIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HEMODIALYSIS; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; NEUTROPHIL CHEMOTAXIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN ISOLATION; UREMIA;

EID: 0031890805     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Mailloux LU, Bellucci AG, Wilkes BM, Napolitano B, Mossey RT, Lesser M, Bluestone PA: Mortality in dialysis patients: Analysis of the causes of death. Am J Kidney Dis 18: 326-335, 1991
2. Korbet SM, Vonesh EF, Firanek CA: A retrospective assessment of risk factors for peritonitis among an urban CAPD population. Perit Dial Int 13: 126-131, 1993
3. Vanholder R, Van Loo A, Dhondt AM, De Smet R, Ringoir S: Influence of uraemia and haemodialysis on host defence and infection. Nephrol Dial Transplant 11: 593-598, 1996
4. Himmelfarb J, Hakim RJ: Biocompatibility and risk of infection in hemodialysis patients. Nephrol Dial Transplant 9[Suppl 2]: 138-144, 1994
5. Haag-Weber M, Hörl WH: Dysfunction of polymorphonuclear leukocytes in uremia. Semin Nephrol 16: 192-201, 1996
6. Ho-Dac-Pannekeet MM, Krediet RT: Inflammatory changes in vivo during CAPD: What can the effluent tell us. Kidney Int 50[Suppl 56]: S12-S16, 1996
7. Hörl WH, Haag-Weber M, Georgopoulos A, Block LH: Physicochemical characterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells. Proc Natl Acad Sci USA 87: 6353-6357, 1990
8. Cohen G, Haag-Weber M, Mai B, Deicher R, Hörl WH: Effect of immunoglobulin light chains from hemodialysis and continuous ambulatory peritoneal dialysis patients on polymorphonuclear leukocyte functions. J Am Soc Nephrol 6: 1592-1599, 1995
9. 2-microglobulin. Nephrol Dial Transplant 9: 382-388, 1994
10. Haag-Weber M, Mai B, Hörl WH: Impaired cellular host defence in peritoneal dialysis by two granulocyte inhibitory proteins. Nephrol Dial Transplant 9: 1769-1773, 1994
11. Tschesche H, Kopp C, Hörl WH, Hempelmann U: Inhibition of degranulation of polymorphonuclear leukocytes by angiogenin and its tryptic fragments. J Biol Chem 269: 30274-30280, 1994
12. Balke N, Holtkamp U, Hörl WH, Tschesche H: Inhibition of degranulation of human polymorphonuclear leukocytes by complement factor D. FEBS Lett 371: 300-302, 1995
13. Haag-Weber M, Cohen G, Hörl WH: Modulation of granulocyte (PMNL) function by complement factor D isolated from peritoneal dialysis effluent [Abstract]. J Am Soc Nephrol 7: 1480, 1996
14. Vanholder R, De Smet R, Waterloos MA, Van Landschoot N, Vogeleere P, Hoste E, Ringoir S: Mechanisms of uremic inhibition of phagocyte reactive species production: Characterization of the role of p-cresol. Kidney Int 47: 510-517, 1995
15. Metcalf JA, Gallin JI, Nauseef WM, Root RK: Laboratory Manual of Neutrophil Function, New York, Raven, 1986, pp 2-5
16. Nelson RD, Quie PG, Simmons RL: Chemotaxis and spontaneous migration of human polymorphonuclear leukocytes and monocytes. J Immunol 115: 1650-1655, 1975
17. Schlesinger DH, Goldstein G, Niall H: The complete amino acid sequence of ubiquitin, an adenylate cyclase stimulating polypeptide probably universal in living cells. Biochemistry 14: 2214-2218, 1975
18. Vijay-Kumar S, Bugg CE, Cook WJ: Structure of ubiquitin refined at 1.8 Å resolution. J Mol Biol 194: 513-544, 1987
19. Haas AL, Murphy KE, Bright PM: The inactivation of ubiquitin accounts for the inability to demonstrate ATP, ubiquitin-dependent proteolysis in liver extracts. J Biol Chem 260: 4694-4703, 1985
20. Vanholder R, Van Loo A, Dhont AM, De Smet R, Ringoir S: Influence of uraemia and haemodialysis on host defence and infection. Nephrol Dial Transplant 11: 593-598, 1996
21. Vanholder R, Lameire N, Waterloos MA, Van-Landschoot N, De-Smet R, Vogeleere P, Lambert MC, Vijt D, Ringoir S: Disturbed host defence in peritoneal cavity during CAPD: Characterization of responsible factors in dwell fluid. Kidney Int 50: 643-652, 1996
22. Porter CJ, Burden RP, Morgan AG, Daniels I, Fletcher J: Impaired polymorphonuclear neutrophil function in end-stage renal failure and its correction by continuous ambulatory peritoneal dialysis. Nephron 71: 133-137, 1995
23. Leypoldt JK, Cheung AK: Removal of high-molecular-weight solutes during high-efficiency and high-flux haemodialysis. Nephrol Dial Transplant 11: 329-335, 1996
24. Downey GP: Mechanisms of leukocyte motility and chemotaxis. Curr Opin Immunol 6: 113-124, 1994
25. Baggiolini M, Walz A, Kunkel SL: Neutrophil-activating peptide 1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 84: 1045-1049, 1989
26. Marasco WA, Phan SH, Krutzsch H, Showell HJ, Feltner DE, Nairn R, Becker EL, Ward PA: Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. J Biol Chem 259: 5430-5439, 1984
27. Goldstein IM: Chemotactic factor receptors on leukocytes: Scratching the surface. J Lab Clin Med 97: 599-601, 1981
28. Bos HJ, Boorsma DM, Tuk CW, De Veld JC, Van Der Muysenberg AJC, Helmerhorst TJM, Struijk DG, Van Bronswijk, Beelen RHJ: Chemotaxis of the peritoneal cells and the detection of a chemo-attractant in the effluent from peritoneal dialysis patients. Eur J Clin Invest 20: 555-562, 1990
29. Schlesinger DH, Goldstein G: Molecular conservation of 74 amino acid sequence of ubiquitin between cattle and man. Nature 255: 423-424, 1975
30. Goldstein G, Scheid M, Hammerling U, Boyse EA, Schlesinger DH, Niall HD: Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. Proc Natl Acad Sci USA 72: 11-15, 1975
31. Hershko A: Ubiquitin-mediated protein degradation. J Biol Chem 263: 15237-15240, 1988
32. Chau V, Tobias JW, Bachmair A, Marriott D, Ecker DJ, Gonda DK, Varshavsky A: A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 243: 1576-1583, 1989
33. Mitch WE, Jurkovitz C, England BK: Mechanisms that cause protein and amino acid catabolism in uremia. Am J Kidney Dis 21: 91-95, 1993
34. Mitch WE, Goldberg AL: Mechanisms of muscle wasting: The role of the ubiquitin-proteasome pathway. N Engl J Med 335: 1897-1905, 1996
35. Pancré V, Pierce RJ, Foutnier F, Methali M, Delanoye A, Capron A, Auriault C: Effect of ubiquitin on platelet functions: Possible identity with platelet activity suppressive lymphokine (PASL). Eur J Immunol 21: 2735-2741, 1991
36. Okada M, Miyazaki S, Hirasawa Y: Increase in plasma concentration of ubiquitin in dialysis patients: Possible involvement in beta2-microglobulin amyloidosis. Clin Chim Acta 220: 135-144, 1993
37. Roxborough HE, Millar CA, McEneny J, Young IS: Carbamylation inhibits the ferroxidase activity of caeruloplasmin. Biochem Biophys Res Commun 214: 1073-1078, 1995
38. Stark GR, Stein WH, Moore S: Reactions of the cyanate present in aqueous urea with amino acids and proteins. J Biol Chem 235: 3177-3181, 1960
39. Schliecher E, Wieland OH: Protein glycation: Measurement and clinical relevance. J Clin Chem Clin Biochem 27: 577-587, 1989
40. Lamb E, Cattel WR, Dawnay A: Glycated albumin in serum and dialysate of patients on continuous ambulatory peritoneal dialysis. Clin Sci 84: 619-626, 1993